(Q36573907)

15 August 2017

1 reference

title

Sildenafil for pulmonary arterial hypertension: when blue turns into white (English)

1 reference

15 August 2017

main subject

arterial hypertension

1 reference

Sabina A Antoniu

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

published in

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

13

1 reference

15 August 2017

page(s)

1801-1810

1 reference

Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Clinical classification of pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Diagnosis and differential assessment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Beraprost therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Inhaled iloprost for severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Endothelin as a regulator of cardiovascular function in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Survival with first-line bosentan in patients with primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Ambrisentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Sildenafil inhibits hypoxia-induced pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Acute effects of sildenafil in patients with primary pulmonary hypertension receiving epoprostenol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Efficacy and optimal dose of sildenafil in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Early haemodynamic benefit of sildenafil in patients with coexisting chronic thromboembolic pulmonary hypertension and left ventricular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Pulmonary arterial hypertension associated to connective tissue diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Long-Term Treatment With Oral Sildenafil Is Safe and Improves Functional Capacity and Hemodynamics in Patients With Pulmonary Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Sildenafil citrate therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Goal-oriented treatment and combination therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Sildenafil for pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

PDGF signaling in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1801

10.1517/14656566.7.13.1801

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference